Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Class action sits at the center of this dementia and brain health question.
While major class action litigation specifically targeting sleep aid manufacturers over dementia claims has not yet emerged as of April 2026, there is substantial scientific evidence driving increased scrutiny of common sleep medications and their long-term cognitive effects. Recent research on anticholinergic drugs—a class that includes popular over-the-counter sleep aids like diphenhydramine (found in Benadryl PM and similar products)—has revealed a significant association with dementia risk, creating the legal and scientific foundation for potential future litigation. Consumers who have relied on these medications for years are now facing difficult questions about whether their sleep solutions may have contributed to cognitive decline.
The conversation around sleep aids and dementia risk reflects a broader pattern in pharmaceutical litigation: scientific evidence of potential harm accumulates, regulatory oversight lags, and eventually class actions emerge. We’ve already seen this unfold with gabapentin, where users have filed lawsuits over dementia risks despite the drug not being primarily marketed as a sleep aid. The same mechanism could apply to over-the-counter and prescription sleep medications that contain anticholinergic compounds or benzodiazepines, both of which have been linked to increased dementia and Alzheimer’s risk in peer-reviewed studies.
Table of Contents
- What Are Anticholinergic Sleep Aids and Why Are They Being Scrutinized?
- Benzodiazepines and the Stronger Dementia Connection
- Gabapentin Litigation: A Preview of What May Come
- Why Older Adults Are Most Vulnerable to Sleep Aid Risks
- Documentation and Your Medical Records Matter
- Safer Sleep Alternatives to Consider
- The Future of Sleep Aid Litigation and Regulation
- Conclusion
What Are Anticholinergic Sleep Aids and Why Are They Being Scrutinized?
anticholinergic drugs work by blocking acetylcholine, a neurotransmitter critical to memory and learning. Many common OTC sleep aids—including diphenhydramine, found in products sold under names like Benadryl PM, Tylenol PM, and various store-brand sleep aids—fall into this category. They’re available without prescription, affordable, and widely used by millions of Americans, particularly older adults who struggle with insomnia. What makes them appealing to consumers—their accessibility and low cost—is also what makes widespread, long-term use so concerning from a neurological perspective. A landmark study from Indiana University tracked over 3,400 adults aged 65 and older for an average of seven years and found that long-term use of anticholinergic drugs was significantly associated with increased dementia risk.
The research, referenced by Harvard Health, didn’t just show a minor correlation; it demonstrated a measurable cognitive impact. For someone taking these sleep aids nightly for months or years—a common pattern among older adults with chronic insomnia—the cumulative exposure to anticholinergic effects adds up significantly. The concerning part is that many people taking these medications have no idea they’re anticholinergic, assuming they’re simply “gentle” OTC sleep aids. The limitation of current research is that it shows correlation rather than definitive causation, and individual risk varies based on factors like genetics, overall health, duration of use, and dosage. However, the consistency of findings across multiple studies—showing that long-term use of strong anticholinergics increased dementia risk by more than 50%—is substantial enough that medical organizations now recommend older adults avoid these medications when possible.
Benzodiazepines and the Stronger Dementia Connection
Prescription sleep aids in the benzodiazepine class (such as diazepam, lorazepam, and others) carry an even more dramatic dementia risk profile than anticholinergic OTC sleep aids. Research cited by Harvard Health found that adults taking benzodiazepines for just 3 to 6 months had a 32% greater risk of Alzheimer’s disease, but those taking them for longer than 6 months had an 84% greater risk. This dramatic increase in risk with extended use explains why these medications are now recommended only for short-term management of acute anxiety or insomnia—not the chronic sleep problems many patients face. The warning here is critical: benzodiazepines are still widely prescribed for sleep despite these risks, sometimes for extended periods.
Patients and doctors alike may underestimate the cognitive consequences of long-term benzodiazepine use, particularly in older adults whose brains are already vulnerable to age-related cognitive decline. The 84% increased risk of Alzheimer’s after six months of use is a substantial number that should prompt serious conversations between patients and their physicians about alternative approaches. Yet many people remain on these medications for years, often because they’re effective for sleep but also because discontinuing them can be difficult due to dependence and withdrawal effects. A significant limitation of patient choices is that the most effective sleep medications carry the highest dementia risks, while safer alternatives (like melatonin, valerian root, or cognitive behavioral therapy for insomnia) may be less effective for severe sleep disturbance. This creates a tragic trade-off where patients managing severe insomnia must choose between better sleep and cognitive protection.
Gabapentin Litigation: A Preview of What May Come
While gabapentin (Neurontin) is not primarily marketed as a sleep aid, it is frequently prescribed off-label for insomnia and is one of the most commonly used medications in America. Gabapentin litigation is now active, with users filing lawsuits over dementia risks. The criteria established in gabapentin cases typically include documented use of the medication at least 6 times between 2000 and 2024, combined with an early-onset dementia diagnosis before age 65.
This litigation framework, established through firms like Sokolove Law and others handling gabapentin claims, provides a template for how sleep aid litigation might develop. The gabapentin example demonstrates that dementia-related drug litigation doesn’t require FDA approval to be pulled or widespread recalls—it requires documentation of use, medical diagnosis of cognitive decline, and a scientific theory linking the two. The same documentation exists for anticholinergic sleep aids and benzodiazepines: millions of prescriptions, decades of use, and peer-reviewed studies showing dementia associations. If gabapentin users have successfully pursued litigation, sleep aid users with documented long-term use and subsequent dementia diagnosis may eventually have similar legal avenues available.
Why Older Adults Are Most Vulnerable to Sleep Aid Risks
Older adults represent the largest population using both OTC anticholinergic sleep aids and prescription benzodiazepines for sleep. They’re also the population most vulnerable to dementia—making them doubly at risk. When a 70-year-old takes an anticholinergic sleep aid nightly, their aging brain is simultaneously experiencing normal age-related cognitive decline while also being exposed to a drug that impairs acetylcholine function, the very neurotransmitter critical to maintaining memory and mental clarity. The compounding effect is significant.
Additionally, older adults often take multiple medications simultaneously—a practice called polypharmacy. Even if their sleep aid alone poses moderate risk, when combined with other anticholinergic medications (antihistamines, certain antidepressants, anticholinergic bladder medications), the total anticholinergic burden on the brain becomes substantial. A 75-year-old taking a nightly sleep aid plus an antihistamine for allergies plus a medication for overactive bladder may be receiving a high cumulative anticholinergic dose that multiplies dementia risk. This comparison between single-drug use and polypharmacy is critical: the research on sleep aids alone may underestimate the actual risk for patients taking multiple anticholinergic medications.
Documentation and Your Medical Records Matter
If you’ve been taking sleep aids regularly for years, your medical records become crucial documentation. The gabapentin litigation example shows that specific details matter: dates of use, dosages, frequency, and medical records documenting cognitive decline all support potential claims. Someone who took diphenhydramine nightly from 2010 to 2024 and was subsequently diagnosed with early-onset dementia or mild cognitive impairment has documented evidence of exposure and harm. The warning here is that many people don’t realize they should be documenting their medication use in detail until a health problem emerges.
If you or a family member is concerned about past sleep aid use and current cognitive changes, gathering pharmacy records, doctor’s notes, and medical documentation now is important. Additionally, if you have a dementia diagnosis and have used anticholinergic sleep aids or benzodiazepines long-term, discussing the potential connection with your neurologist or geriatrician may reveal whether your case fits patterns being documented for potential litigation. A limitation to understand is that establishing direct causation between a sleep aid and dementia is scientifically difficult and legally complex. However, probabilistic harm—where a medication increases your risk category—may be sufficient for class action litigation, as it has been in other pharmaceutical cases.
Safer Sleep Alternatives to Consider
If you’re currently taking anticholinergic or benzodiazepine sleep aids and concerned about dementia risk, safer alternatives exist. Cognitive behavioral therapy for insomnia (CBT-I) is among the most effective non-medication approaches and actually improves sleep long-term without cognitive side effects. Melatonin supplements, while not universally effective, carry no dementia risk. Low-dose doxepin (Silenor), a sedating antidepressant with minimal anticholinergic effects, is another option some physicians consider.
Sleep hygiene optimization—consistent bedtimes, cool dark bedrooms, limited screen time before bed—remains foundational. The practical trade-off is that these alternatives often require more effort than taking a pill, and they may be less immediately effective for severe insomnia. A 65-year-old who has slept poorly for a decade and finally found relief with a benzodiazepine may feel resistant to switching medications, fearing a return to sleepless nights. However, gradual discontinuation under medical supervision, combined with behavioral approaches, has shown success in many cases and preserves cognitive function long-term.
The Future of Sleep Aid Litigation and Regulation
The pattern is becoming clear: scientific evidence accumulates, consumer groups become aware, litigation follows. We’ve seen this with talc and ovarian cancer, with opioids and addiction, and increasingly with medications linked to cognitive decline. Sleep aids will likely follow this trajectory.
As more dementia cases are documented in patients with long-term sleep aid use, as law firms begin analyzing case patterns, and as regulatory agencies consider warnings or restrictions, the conditions for class action litigation will crystallize. Looking ahead, we may see FDA label changes requiring stronger warnings about dementia risks, especially for long-term use. We may see restrictions on anticholinergic sleep aids for patients over a certain age, or requirements for cognitive monitoring in those taking these medications long-term. The regulatory and litigation landscape for sleep aids is likely to shift substantially over the next five years as awareness grows and evidence accumulates.
Conclusion
While a major class action lawsuit specifically targeting sleep aid manufacturers over dementia claims has not yet materialized as of April 2026, the scientific evidence supporting such litigation is substantial and growing. Millions of people have taken anticholinergic sleep aids and benzodiazepines for years without understanding the potential long-term cognitive consequences. The 50%+ increased dementia risk associated with long-term anticholinergic use and the 84% increased Alzheimer’s risk from benzodiazepines lasting more than 6 months represent serious health concerns that will likely generate legal action as awareness increases.
If you’ve used sleep aids long-term, now is the time to discuss cognitive risks with your physician, document your medication history, and explore safer alternatives. For those who have already experienced cognitive decline after years of sleep aid use, gathering medical documentation and understanding your potential legal options may become important. The litigation landscape for sleep-related medications is shifting, and the scientific foundation for lawsuits is already in place—making this an area where staying informed matters for your health and your potential legal protection.
You Might Also Like
- FDA Issues Warning About Common Sleep Aid Linked to Dementia Risk
- Walgreens Recalls Sleep Aid After FDA Links It to Dementia Cases
- Johnson and Johnson Settles $9 Billion Lawsuit Over Talc Linked to Dementia
For more, see Alzheimer’s Association — clinical trials.
